Literature DB >> 7541588

The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration.

J M Monda1, R P Myers, D G Bostwick, J E Oesterling.   

Abstract

OBJECTIVES: To determine if the serum testosterone (T) concentration influences the ability of prostate-specific antigen (PSA) to predict prostate cancer volume and stage.
METHODS: One hundred consecutive patients with clinically localized prostate cancer who underwent radical prostatectomy were examined prospectively. Each patient was evaluated preoperatively with a serum PSA, total T, free T, and percent free T. All surgical specimens were evaluated using the whole mount, step section technique for Gleason score, tumor volume, and extraprostatic disease.
RESULTS: Serum total T, free T, and percent free T did not correlate with the serum PSA level (r = .03, .08, and .07, respectively), tumor volume (r = .11, .08, and .11, respectively), prostate weight (r = .00, -.08, and .11, respectively), or Gleason score (r = .11, .08, and .11, respectively). Serum PSA correlated with tumor volume (r = .51, P < 0.0001). Extraprostatic disease was significantly associated with a higher percent free T value (r = .26, P = 0.02) but not with either the total or the free T level. Linear regression analysis showed that neither the total nor the free T concentration was a significant predictor of extraprostatic disease in the presence of PSA (P = 0.30 and 0.24, respectively); percent free T contributed only slightly to PSA in the prediction of extraprostatic disease (P = 0.05). However, neither total T, free T, nor percent free T was a significant predictor of tumor volume; in essence, the association between PSA and tumor volume was independent of the serum T concentration (P = 0.30, 0.24, and 0.60, respectively).
CONCLUSIONS: Serum total T, free T, and percent free T values do not enhance the ability of PSA to predict the tumor volume or pathologic stage in patients with clinically localized prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541588     DOI: 10.1016/S0090-4295(99)80160-5

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients.

Authors:  Antonio B Porcaro; Filippo Migliorini; Mario Romano; Aldo Petrozziello; Stefano Zecchini Antoniolli; Emanuele Rubilotta; Vincenzo Lacola; Teodoro Sava; Claudio Ghimenton; Beatrice Caruso; Carmelo Monaco; Luigi Comunale
Journal:  Int Urol Nephrol       Date:  2009-11-10       Impact factor: 2.370

2.  Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer.

Authors:  Antonio B Porcaro; Salvatore Siracusano; Nicolò de Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Tania Processali; Davide Inverardi; Giovanni Cacciamani; Daniele Mattevi; Maria A Cerruto; Matteo Brunelli; Claudio Ghimenton; Carmelo Monaco; Walter Artibani
Journal:  Curr Urol       Date:  2017-10-22

3.  Prostate resected weight and postoperative prostate cancer incidence after transurethral resection of the prostate: A population-based study.

Authors:  Fu-Chao Liu; Kuo-Chun Hua; Jr-Rung Lin; See-Tong Pang; Huang-Ping Yu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

4.  Prostate cancer volume associates with preoperative plasma levels of testosterone that independently predicts high grade tumours which show low densities (quotient testosterone/tumour volume).

Authors:  Antonio B Porcaro; Aldo Petrozziello; Matteo Brunelli; Filippo Migliorini; Giovanni Cacciamani; Davide De Marchi; Nicolo' de Luyk; Irene Tamanini; Beatrice Caruso; Maria A Cerruto; Claudio Ghimenton; Walter Artibani
Journal:  Asian J Urol       Date:  2015-11-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.